Immunome (IMNM) Total Current Liabilities (2019 - 2026)

Immunome's Total Current Liabilities history runs 8 years deep, the most recent figure standing at $27.4 million for Q1 2026.

• Quarterly Total Current Liabilities fell 10.99% year-over-year to $27.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.4 million (down 10.99% YoY) and the FY2025 annual result came in at $45.0 million, down 17.16% from the prior year.
• Total Current Liabilities was $27.4 million for Q1 2026 at Immunome, down from $45.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $54.3 million in Q4 2024 and bottomed at $7.3 million in Q4 2022.
• A 5-year average of $26.5 million and a median of $26.4 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities jumped 213.62% — and 2025, when it tumbled 42.66%.
• Immunome's Total Current Liabilities stood at $7.3 million in 2022, then surged by 197.76% to $21.8 million in 2023, then jumped by 148.78% to $54.3 million in 2024, then retreated by 17.16% to $45.0 million in 2025, then slumped by 39.07% to $27.4 million in 2026.
• Business Quant data shows IMNM's Total Current Liabilities at $27.4 million in Q1 2026, $45.0 million in Q4 2025, and $31.4 million in Q3 2025.